Send to:

Choose Destination
See comment in PubMed Commons below
Clin Cancer Res. 2011 Sep 15;17(18):5841-3. doi: 10.1158/1078-0432.CCR-11-1768.

Better late than early: FDG-PET imaging in metastatic renal cell carcinoma.

Author information

  • 1Divisions of Medical Oncology, Department of Medicine, and Urology, Duke University Medical Center, Durham, North Carolina, USA.


Sunitinib treatment benefits patients with metastatic renal cell carcinoma (mRCC), but response duration can vary widely and resistance is not predicted by standard measures. [¹⁸F]fluoro-2-deoxy-2-D-glucose positron emission tomography (FDG-PET) uptake is variable in mRCC, but changes in FDG-PET uptake may be useful in monitoring disease progression. Further work is needed to personalize treatment for patients with mRCC.

©2011 AACR.

[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk